Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy (Coqueluche-Vac)

Université de Reims Champagne-Ardenne

Status: Not yet enrolling

Conditions: Pertussis

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT06114160

2023_RIPH_015_Coqueluche-Vac

Details and patient eligibility

About

In France, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation.

This vaccination schedule is inspired by the Anglo-Saxon model and studies showing the effectiveness of this practice.

The aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because Pertussis is a particularly serious disease in newborns.

Full description

The aim is to describe pregnant women's knowledge concerning pertussis, vaccination against pertussis during pregnancy and the cocooning strategy.

Enrollment: 500 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Pregnant between 20 and 41 weeks of amenorrhea
• Primiparous
• aged more than 18
• Agreed to participate in the study

Exclusion criteria

• Multiparous
• Protected by law (guardianship, guardianship, safeguarding of justice)
• Not agreed to participate in this study

Trial design

500 participants in 1 patient group

pregnant women

Description:

Pregnant women between 20 and 41 weeks of amenorrhoea, primiparous.

Treatment:

Other: Data collection